Hemophilia

1
Hemophilia

• U I Inc., USA
• Payor Education Presentation

Last Updated January, 2012
2
Hemophilia
Facts

• Chronic genetic disorder characterized by a
  protein deficiency that results in delayed blood
  clotting.
• Individuals with hemophilia typically have
  internal bleeds affecting their joints and
  muscles.
• While hemophilia is the result of a mutation on
  the X chromosome, approximately 33 of cases are
  random mutations and not inherited.
• Since the mutation is located on the X
  chromosome, males (having only one X) tend to be
  more symptomatic than females.
• Hemophilia A is the deficiency of the Factor
  VIII protein.
• Hemophilia B is the deficiency of the Factor IX
  protein.

3
Hemophilia
By the Numbers

• There are roughly 20,000 hemophiliacs in the US,
  nationwide.
• Hemophilia A accounts for about 80 of the cases
  while Hemophilia B makes up the other 20.
• Severe hemophilia accounts for roughly 50 of
  all cases in the United States.
• Moderate and mild hemophilia each make up
  approximately 25 of the cases.
• The average medical cost for a person with
  hemophilia (using all severities and both
  Hemophilia A B) is approximately 150,000.
• Clotting factor replacement products account for
  about 90 of hemophiliacs annual medical costs.
• The average cost for one dose of factor
  replacement is 1,500 - 2000 and near 30 of
  bleeds require more than one dose.

4
Hemophilia
Treatment

• Treatments for hemophilia include intravenous
  clotting factor replacement, icing the injury
  site, as well as compression and elevation of the
  site.
• In order to avoid costly delays that cause a
  bleeding episode to get worse and therefore
  require more factor and time in order to recover,
  most individuals are trained to infuse by
  themselves at home.
• Factor replacement therapy can take three forms
  (which form should be utilized is determined by
  the patient and their doctor)
• Scheduled prophylaxis treatment is used to
  maintain a safe level of clotting protein through
  intravenous infusions on a regular basis.
• Some people infuse prior to a more physical
  activity such as jogging or biking to prevent
  bleeds at that time, however they do not infuse
  on a regular schedule.
• Others wait until they have a bleed occur before
  undergoing therapy.

5
Hemophilia
Complications

• Many Complication can cause the costs of
  treating a person with hemophilia to increase.
• here are several complications that are
  frequently seen with hemophilia population.
• Co-morbidities such as HIV infection and
  Hepatitis can mean additional medications and
  doctors visits and/or hospitalizations that drive
  up cost of care. (Luckily HIV and Hepatitis have
  not been known to be transmitted through factor
  use for many years, meaning that these really
  only impact the older generations now.)
• Inhibitors result from the individuals immune
  system rejecting the clotting factor used in the
  replacement therapy. When this occurs, the cost
  of treatment and factor usage can skyrocket.
• Roughly 33 of the people with severe hemophilia
  develop inhibitors.
• Immune tolerance therapy (also called Inhibitor
  Override Therapy) and bypass therapy are the
  primary treatments for inhibitor patients.
• Once a person begins Override Therapy, compliance
  to the treatment regimen is critical to success
  which means long term quality of life
  improvements as well as large cost reductions.
• Joint damage is a large cause of long term
  problems and recurring bleeding episodes.
  Treating a joint bleed correctly when they do
  occur can prevent or limit the long term damage,
  preventing many target joints from developing and
  greatly reducing the time and factor needed to
  recover when they do occur. To this end,
  clinical management and outcomes monitoring is an
  important part of cost reduction.

6
Hemophilia
why ui?

• at U I, HEMOPHILIA IS OUR ONLY BUSINESS
• U IS UTILIZATION MANAGEMENT PROGRAM
  SIGNIFICANTLY LOWERS HEMOPHILIA COSTS AND
  IMPROVES QUALITY OF LIFE
• U I UTILIZATION COST FOCUS HEMOPHILIA SELF
  CARE EDUCATION, BLEEDING PREVENTION, REDUCING
  INFUSION, AND ASSAY MANAGEMENT
• U I UTILIZATION MANAGEMENT PROCESS
• ASSESSMENT/MONITORING OF RISK WITH MEASUREMENT
  OF TREATMENT/COMPLIANCE
• PRODUCTS/SERVICES/EDUCATION
• PERSONAL DELIVERY INTERVENTION
• CONTINUITY OF CARE WITH HTC/PAYOR
• OUTCOMES REPORTING

7
Hemophilia
Payor Education Presentation

• U I Inc., USA
• 5236 West Seneca St.
• Vernon, NY 13476
• info_at_unipartners.net
• 877 229 - 5248